Physician profile
Hector Marchand
NPI 1134474091
$16,092.14
in general payments reported to CMS, 2019-2025
68 companies · $2,423 in 2025
The $2,423 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,786 · 2020: $1,171 · 2021: $1,976 · 2022: $2,595 · 2023: $3,102 · 2024: $3,038 · 2025: $2,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,563.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,827.09 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,672.39 | 2019-2025 | |
| Novo Nordisk INC | $1,645.04 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,338.06 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $889.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $690.45 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $531.57 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Abbott Laboratories | $444.32 | 2023-2025 | Cardiomems, Freestyle Libre 3 |
| Astellas Pharma US INC | $411.30 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $405.90 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $390.82 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $353.35 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $324.84 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $307.35 | 2019-2023 | Spravato |
| Allergan, INC. | $299.93 | 2019 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $268.47 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $262.39 | 2019-2023 | |
| Boston Scientific Corporation | $239.22 | 2021-2023 | Watchman Flx |
| Esperion Therapeutics, INC. | $216.37 | 2020-2024 | Nexletol |
| Axsome Therapeutics, INC. | $201.05 | 2023-2025 | Auvelity |
| Mylan Specialty L.P. | $200.56 | 2019-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $196.91 | 2019-2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $188.32 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $184.77 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Ibsa Pharma INC. | $180.25 | 2020-2023 | Tirosint, Licart |
| Amarin Pharma, INC. | $165.62 | 2020-2022 | |
| Exact Sciences Corporation | $165.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insulet Corporation | $162.88 | 2019-2022 | |
| Dexcom, INC. | $161.48 | 2021-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $144.14 | 2022 | |
| Radius Health, INC. | $106.65 | 2023-2025 | Tymlos |
| Vanda Pharmaceuticals INC. | $105.82 | 2021-2025 | Fanapt |
| Lundbeck LLC | $98.36 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $91.65 | 2022-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $86.55 | 2022 | |
| Vifor Pharma, INC. | $85.46 | 2019-2021 | |
| Scpharmaceuticals INC. | $75.09 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $74.94 | 2020-2024 | |
| Almatica Pharma LLC | $73.06 | 2025 | Loreev Xr |
| Xeris Pharmaceuticals, INC. | $69.57 | 2023-2024 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $69.43 | 2023-2024 | Unithroid |
| Sumitomo Pharma America, INC. | $65.64 | 2023-2024 | Gemtesa |
| Edwards Lifesciences Corporation | $56.83 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Biohaven Pharmaceuticals, INC. | $55.44 | 2021 | |
| Vivus LLC | $47.46 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $44.77 | 2025 | Zenpep |
| Arbor Pharmaceuticals, INC. | $36.92 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $28.63 | 2022-2023 | Contrave |
| Alnylam Pharmaceuticals INC. | $27.92 | 2023 | Onpattro |
| Tactile Systems Technology INC | $27.82 | 2024 | Entre Plus, Flexitouch Plus |
| Regeneron Healthcare Solutions, INC. | $25.93 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.65 | 2025 | Qelbree, Xyosted, Tlando |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.83 | 2025 | Caplyta |
| Electromed, INC. | $19.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.72 | 2022 | |
| Alkermes, INC. | $16.84 | 2021 | |
| Halozyme INC | $16.23 | 2023 | |
| Antares Pharma, INC. | $15.93 | 2024 | Xyosted |
| Philips North America LLC | $15.31 | 2023 | |
| Alfasigma USA, INC. | $14.96 | 2021 | |
| Neurocrine Biosciences, INC. | $14.90 | 2025 | |
| Horizon Therapeutics Plc | $14.88 | 2022 | |
| Sanofi Pasteur INC. | $14.79 | 2023 | |
| Genentech USA, INC. | $14.73 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.01 | 2025 | Nuzyra, Xhance |
| Bausch Health US, LLC | $13.80 | 2020 | |
| Eisai INC. | $12.04 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Marchand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.